Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

OBJECTIVE: To evaluate the psychosocial impact of participation in a population-based prostate-specific antigen (PSA) testing programme, akin to screening, and to explore the relationship between urinary symptoms reported before PSA testing and the response to the subsequent PSA result. PATIENTS AN...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Brindle, L, Oliver, SE, Dedman, D, Donovan, J, Neal, D, Hamdy, F, Lane, J, Peters, T
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2006

Gelijkaardige items

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
door: Moore, A, et al.
Gepubliceerd in: (2009)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
door: Avery, K, et al.
Gepubliceerd in: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
door: Avery, K, et al.
Gepubliceerd in: (2012)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
door: Down, L, et al.
Gepubliceerd in: (2011)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
door: Down, L, et al.
Gepubliceerd in: (2011)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
door: J. Donovan, et al.
Gepubliceerd in: (2003-01-01)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
door: Hamdy, F, et al.
Gepubliceerd in: (2006)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
door: Young, GJ, et al.
Gepubliceerd in: (2017)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
door: Hamdy, F, et al.
Gepubliceerd in: (2006)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
door: Macefield, R, et al.
Gepubliceerd in: (2009)

The value of repeat serum PSA measurements in the detection of prostate cancer - Experience from the feasibility phase of the UK protect study
door: Hamdy, F, et al.
Gepubliceerd in: (2006)

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
door: Avery, K, et al.
Gepubliceerd in: (2008)

Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer.
door: Oliver, SE, et al.
Gepubliceerd in: (2004)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
door: Rosario, D, et al.
Gepubliceerd in: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
door: Rosario, D, et al.
Gepubliceerd in: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
door: Rosario, D, et al.
Gepubliceerd in: (2012)

Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
door: Williams, N, et al.
Gepubliceerd in: (2011)

Prostate-specific antigen testing rates remain low in UK general practice: A cross-sectional study in six English cities
door: Williams, N, et al.
Gepubliceerd in: (2011)

The protect (prostate testing for cancer and treatment) study: Advanced cases found through a UK screening study
door: Neal, D, et al.
Gepubliceerd in: (2006)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
door: Rosario, D, et al.
Gepubliceerd in: (2008)

Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes
door: Simpkin, A, et al.
Gepubliceerd in: (2013)

ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY
door: Collin, S, et al.
Gepubliceerd in: (2009)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
door: Burton, A, et al.
Gepubliceerd in: (2011)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
door: Harrison, S, et al.
Gepubliceerd in: (2020)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
door: Vickers, A, et al.
Gepubliceerd in: (2010)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
door: Collin, S, et al.
Gepubliceerd in: (2009)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
door: Lane, J, et al.
Gepubliceerd in: (2010)

Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer.
door: Collin, S, et al.
Gepubliceerd in: (2010)

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
door: Turner, E, et al.
Gepubliceerd in: (2011)

Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
door: Tilling, K, et al.
Gepubliceerd in: (2010)

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
door: Oliver, SE, et al.
Gepubliceerd in: (2004)

Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
door: Harrison, S, et al.
Gepubliceerd in: (2016)

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
door: Lane, J, et al.
Gepubliceerd in: (2007)

Measurement of the insulin-like growth factor (IGF)-axis does not enhance the specificity of PSA-based prostate cancer screening.
door: Oliver, SE, et al.
Gepubliceerd in: (2002)

Screening for prostate cancer. The case against.
door: Donovan, J, et al.
Gepubliceerd in: (2005)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
door: Avery, K, et al.
Gepubliceerd in: (2007)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
door: Donovan, J, et al.
Gepubliceerd in: (2003)

10-year outcomes in localized prostate cancer.
door: Hamdy, F, et al.
Gepubliceerd in: (2017)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
door: Lane, J, et al.
Gepubliceerd in: (2009)

Prostate cancer: screening approaches.
door: Donovan, J, et al.
Gepubliceerd in: (2005)